T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals is a research paper published in Cell (2022). On theSindex it has a DataRank of 0. It has been cited 260 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIDDK NIH HHS
Grant: P01 DK011794
CCR NIH HHS
Grant: HHSN261200800001C
NIAID NIH HHS
Grant: DP2 AI154421
NIAID NIH HHS
Grant: UM1 AI144462
NCI NIH HHS
Grant: HHSN261200800001E
NIDA NIH HHS
Grant: DP2 DA040254
NIAID NIH HHS
Grant: R01 AI149704
NIGMS NIH HHS
Grant: T32 GM007753
National Institutes of Health
Grant: 5P01DK011794-24
HORMONAL CONTROL OF CALCIUM METABOLISM
National Institutes of Health
Grant: 5DP2AI154421-04
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV Cure
National Institutes of Health
Grant: 1DP2DA040254-01
Engineering Humoral Immunity to Functionally Cure HIV Infection
National Institutes of Health
Grant: 5R01AI149704-02
Understanding and Reversing T Cell Dysfunction to Control and Eliminate Persistent HIV Reservoirs
National Institutes of Health
Grant: 3UM1AI144462-02S1
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antivirals
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents
Additional file 1 of Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents
Additional file 1 of Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination
Additional file 1 of Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination